Drug intelligence / Profile preview

prednisone + tocilizumab

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Subcutaneous

Overview

A combination therapy consisting of prednisone, a synthetic glucocorticoid corticosteroid, and tocilizumab, a recombinant humanized monoclonal antibody that inhibits interleukin-6 (IL-6) receptor. This combination is primarily used for the treatment of giant cell arteritis (GCA), with research showing that 12 months of tocilizumab combined with a shortened 8-week course of prednisone can effectively induce and maintain remission while reducing glucocorticoid exposure and associated toxicity.

Targets

GR (Glucocorticoid receptor)IL-6R (Interleukin-6 receptor subunit alpha)

Beyond the preview

Go deeper on prednisone + tocilizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednisone + tocilizumab.

Explore the full profile